Aqsens Health and NMIMR on the path towards the commercialization of AQ Malaria
Aqsens Health and the Noguchi Memorial Institute for Medical Research’s project to improve malaria screening and rapid diagnostics has raised interest, received new funding, and is on the path towards commercialisation.
Aqsens Health received a meaningful contribution to its research and validation project in Ghana from the Finnpartnership business partnership program funded by the Ministry for Foreign Affairs of Finland.
“This contribution is more than just financial support, as it will strengthen our governmental partnerships and long term commitment to improving infectious diseases diagnostics in Ghana as well as in other African countries”, says Vilhelmiina Juusti, who leads the Malaria Detection project at Aqsens Health.
“It will also be a crucial step in piloting the AQ Malaria test in West-Africa,” she continues.
“We have followed Aqsens Health for a while and seen their dedication in introducing novel disease detection technologies developed in Finland to help low-income countries combat infectious diseases. We’re happy to be involved in a project that will bring new innovation and technological know-how to Ghana while at the same time helping manage malaria,” says Finnpartnership programme director Birgit Nevala.
“Finnpartnership’s interest and advice throughout the beginning stages of the project with Noguchi has been invaluable,” Vilhemiina concludes.
The research collaboration with the NMIMR has progressed as planned. The Noguchi research team has finished collecting 2000 saliva samples, and next a team from Finland will travel to Ghana to begin analysis together with the E-TRF –method certified team currently working in Accra. Dr. Linda Amoah continues to lead the sample collection and research at the NMIMR.
“I am very happy that Aqsens has received additional funds to continue the malaria project in Ghana and expand the project to include research and development of non-invasive diagnostics for other infectious diseases of public health importance,” says Dr. Amoah.
Both Aqsens Health and the NMIMR are looking forward to a long term research collaboration, starting from malaria and moving on to Tuberculosis and Cholera. This government contribution will pave the way forward to help the parties build future success stories in the early detection of lethal infectious diseases.
For more information, contact:
CEO and Co-Founder
Timo Teimonen
+358 40 5853105
timo.teimonen@aqsens.com
Aqsens Health Oy is a Finnish health- and biotechnology startup developing non-invasive screening tests for different high-impact diseases. The company’s current research projects focus on developing a mobile screening platform fit for the needs of developing economies, and establishing a reliable and cost-efficient screening test for prostate cancer. The tests use Aqsens Health’s novel E-TRF technology in combination with bacteriophage-biosensors. The company’s laboratories and main office are located in Turku, Finland, with another office in the capital Helsinki.
